Quent Capital LLC Buys 87 Shares of Stryker Co. (NYSE:SYK)

Quent Capital LLC increased its stake in shares of Stryker Co. (NYSE:SYK) by 4.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,144 shares of the medical technology company’s stock after acquiring an additional 87 shares during the quarter. Quent Capital LLC’s holdings in Stryker were worth $775,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Centennial Bank AR boosted its holdings in shares of Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares during the last quarter. Central Pacific Bank Trust Division bought a new position in Stryker during the first quarter valued at approximately $39,000. HBW Advisory Services LLC bought a new position in Stryker during the third quarter valued at approximately $42,000. Accent Capital Management LLC bought a new stake in Stryker in the 4th quarter worth approximately $60,000. Finally, Sachetta LLC raised its holdings in shares of Stryker by 16.3% during the 2nd quarter. Sachetta LLC now owns 242 shares of the medical technology company’s stock worth $80,000 after acquiring an additional 34 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on SYK. Evercore ISI raised their target price on shares of Stryker from $365.00 to $380.00 and gave the company an “outperform” rating in a report on Tuesday. Stifel Nicolaus reduced their target price on shares of Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Royal Bank of Canada restated an “outperform” rating and set a $386.00 target price on shares of Stryker in a research report on Wednesday, July 31st. Needham & Company LLC lifted their price target on Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Finally, Piper Sandler restated an “overweight” rating and issued a $380.00 price target on shares of Stryker in a research report on Tuesday, September 10th. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $379.37.

Insider Buying and Selling at Stryker

In other news, insider Viju Menon sold 600 shares of Stryker stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Viju Menon sold 600 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Glenn S. Boehnlein sold 20,000 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $333.00, for a total value of $6,660,000.00. Following the transaction, the chief financial officer now directly owns 2,852 shares in the company, valued at $949,716. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 220,068 shares of company stock valued at $71,811,372. 5.90% of the stock is currently owned by insiders.

Stryker Stock Down 0.1 %

Shares of NYSE SYK traded down $0.39 during midday trading on Friday, reaching $351.22. 676,931 shares of the company’s stock traded hands, compared to its average volume of 1,270,464. The company has a market cap of $133.80 billion, a price-to-earnings ratio of 40.09, a P/E/G ratio of 2.74 and a beta of 0.91. The stock’s 50 day simple moving average is $349.77 and its 200-day simple moving average is $343.16. The company has a quick ratio of 0.95, a current ratio of 1.68 and a debt-to-equity ratio of 0.51. Stryker Co. has a one year low of $249.98 and a one year high of $374.63.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.79 by $0.02. The business had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter last year, the firm earned $2.54 EPS. On average, analysts predict that Stryker Co. will post 12 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a $0.80 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a yield of 0.91%. Stryker’s dividend payout ratio is presently 36.53%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.